Literature DB >> 9158007

Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.

D Lazzereschi1, A Ranieri, G Mincione, S Taccogna, F Nardi, G Colletta.   

Abstract

Transforming growth factor beta (TGF-beta) is a physiological regulator of thyroid epithelial cell growth and differentiation. This factor signals through a heteromeric complex composed of type I (TGF-beta receptor type I) and type II [TGF-beta receptor type II (TbetaRII)] receptors. Loss of TbetaRII expression has been related to resistance to TGF-beta inhibition of cell proliferation. In the present work, we analyzed the TbetaRII expression in a series of human thyroid tumors, from benign lesions (adenomas) to neoplastic lesions of increasing aggressiveness (papillary and follicular carcinomas) up to the extremely aggressive anaplastic tumors. Results obtained indicated a clear reduced expression of TbetaRII mRNA only in the group of thyroid carcinomas when compared with their relative normal tissues. Immunohistochemical analyses with specific anti-TbetaRII antibodies confirm these observations. These data indicate that loss of expression of TbetaRII can contribute to thyroid cancer progression, inducing cancer cells to escape the growth-inhibitory effect of TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158007

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.

Authors:  H Ikeda; T Yoshimoto; N Shida; I Miyoshi; K Nakayama; K Nakayama; M Oshima; M M Taketo
Journal:  Endocrine       Date:  2001-10       Impact factor: 3.633

2.  Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.

Authors:  A Franchi; O Gallo; I Sardi; M Santucci
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

3.  Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression.

Authors:  Fancai Zeng; Guoxiong Xu; Tiejun Zhou; Chengwan Yang; Xinyan Wang; Chun Peng; Hong Zhou
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

4.  Reduction of invasive potential in K-ras-transformed thyroid cells by restoring of TGF-beta pathway.

Authors:  Arianna Nicolussi; Sonia D'Inzeo; Angela Gismondi; Anna Coppa
Journal:  Clin Exp Metastasis       Date:  2006-11-03       Impact factor: 5.150

5.  Expression of transforming growth factor betas and their signaling receptors in stone-containing intrahepatic bile ducts and cholangiocarcinoma.

Authors:  King-Teh Lee; Tsan-Shium Liu
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

6.  Analysis of TGF-B and TGF-B-RII in Thyroid Neoplasms from the United States, Japan, and China.

Authors:  Yoshiaki Imamura; Long Jin; Joseph P. Grande; Chin-Yang Li; T-R. Zheng; Lori A. Erickson; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

7.  Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines.

Authors:  J M Cerutti; K N Ebina; S E Matsuo; L Martins; R M B Maciel; E T Kimura
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

8.  EGF and TGF-β1 Effects on Thyroid Function.

Authors:  Gabriella Mincione; Maria Carmela Di Marcantonio; Chiara Tarantelli; Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Caterina Francesca Donini; Anna Coppa
Journal:  J Thyroid Res       Date:  2011-06-13

9.  Effects of the Smad4 C324Y mutation on thyroid cell proliferation.

Authors:  Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Anna Coppa
Journal:  Int J Oncol       Date:  2013-04-17       Impact factor: 5.650

Review 10.  Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis.

Authors:  G C Hard
Journal:  Environ Health Perspect       Date:  1998-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.